Niklas Landberg

12PUBLICATIONS
89CO-AUTHORS
Gene and molecular therapyHaematological tumoursGene expression (incl. microarray and other genome-wide approaches)Innate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 23, 2026
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.

|Sep 18, 2026
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia.

|Nov 25, 2025
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes.

Henrik Lilljebjörn, Pablo Peña-Martínez, Hanna Thorsson

|Oct 03, 2025
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia.

Carl Sandén, Niklas Landberg, Pablo Peña-Martínez

|Dec 13, 2023
IDH1-mutant preleukemic hematopoietic stem cells can be eliminated by inhibition of oxidative phosphorylation.

Niklas Landberg, Thomas Köhnke, Yang Feng

|Mar 01, 2023
Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy.

Miles H Linde, Amy C Fan, Thomas Köhnke

Pageof 2

Frequent Collaborators

7 joint publications

Vladimir Lj Lazarevic

4 joint publications

Carl Sandén

4 joint publications

Henrik Lilljebjörn

4 joint publications

Ravindra Majeti